QualityStocks would like to highlight
International Stem Cell Corporation (
OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).
In the company’s news,
International Stem Cell Chief Scientific Officer Dr. Ruslan Semechkin is scheduled to present the company’s latest results from its Parkinson’s disease program at the American Neurological Association’s 2013 Annual Meeting October 13 – 15, 2013, in New Orleans.
Dr. Semechkin’s presentation will be conducted in collaboration with the Sanford Burnham Medical Research Institute, and detail new data and results from ISCO’s first primate study, which includes an outline of neural stem cells’ unique mechanism of action, data on the fate of the cells, and a detailed analysis of the primate’s immune response to the implantation.
The presentation will be at the following session:
Date: Monday, October 14, 2013
Time: 11:00 am – 7:00 pm
Title: The Use of Neural Stem Cells for the Treatment of Parkinson’s Disease in a Non-Human Primate Model
ISCO’s Parkinson’s disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company’s proprietary histocompatible human pluripotent stem cells.
hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The cells have several characteristics that the company believes offer a new and revolutionary opportunity for the treatment of Parkinson’s disease, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms. hPNSC are able to differentiate into dopaminergic neurons and are able to express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to protect the nigrostriatal system.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
###
